Neurobo Pharmaceuticals Doses First Patient in Its Phase IIA Clinical Trial Evaluating Da-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc. announced dosing of the first patient in its two-part, Phase IIa clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, for the treatment of nonalcoholic steatohepatitis (NASH).